{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-011612","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.747810+00:00","generated_at":"2026-06-17T07:12:11.152966+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revelation Biosciences reports FY2022 net loss $10.8M; cash $5.3M through June 2024","bullets":["Cash and cash equivalents $5.3M at Dec 31, 2022 vs $1.3M year ago; $15.6M public offering completed.","Net loss for FY2022 $10.8M ($20.09 per share) vs $12.0M ($42.50 per share) in 2021.","Operating cash burn $11.2M for FY2022 vs $11.1M in prior year.","Plans to start combined Phase 1a clinical study for REVTx-300 and REVTx-100 in H2 2023.","Management believes cash sufficient to fund operations through June 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-011612","json":"https://secwatch.observer/filing/0000950170-23-011612.json","markdown":"https://secwatch.observer/filing/0000950170-23-011612.md","text":"https://secwatch.observer/filing/0000950170-23-011612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023011612/0000950170-23-011612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023011612/revb-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:12:11.152966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b22d4f79c1525ef38bb7e72bcf160abf1ce91e7","claim":"REVELATION BIOSCIENCES, INC. reported twelve months ended December 31, 2022 results: net income $10.8 million, EPS $20.09 per share.","evidence_excerpt":"Revelation’s net loss for the three and twelve months ended December 31, 2022 was $1.2 million and $10.8 million, or $1.77 per share and $20.09 per share, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023011612/0000950170-23-011612-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"twelve months ended December 31, 2022"},{"label":"Net income","value":"$10.8 million"},{"label":"EPS","value":"$20.09 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"2b21c72521d1c85f1d8eb74b6d39c0f91b17f426","claim":"REVELATION BIOSCIENCES, INC. reported three months ended December 31, 2022 results: net income $1.2 million, EPS $1.77 per share.","evidence_excerpt":"Revelation’s net loss for the three and twelve months ended December 31, 2022 was $1.2 million and $10.8 million, or $1.77 per share and $20.09 per share, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023011612/0000950170-23-011612-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2022"},{"label":"Net income","value":"$1.2 million"},{"label":"EPS","value":"$1.77 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}